已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Intermediate-Dose Cytarabine as Postinduction AML Therapy

阿糖胞苷 医学 肿瘤科 内科学 化疗
作者
Mathilde Hunault,Cécile Pautas,Sarah Bertoli,Pierre‐Yves Dumas,Emmanuel Raffoux,Tony Marchand,Maël Heiblig,Sylvain Chantepie,Martin Carré,Pierre Péterlin,Maria-Pilar Gallego-Hernanz,Émilie Lemasle,Romain Guièze,Célestine Simand,Pascal Turlure,Anne Huynh,Thibaut Leguay,Raynier Devillier,Stéphanie Nguyen,Nicolas Duployez
出处
期刊:NEJM evidence [Massachusetts Medical Society]
卷期号:4 (7): EVIDoa2400326-EVIDoa2400326 被引量:15
标识
DOI:10.1056/evidoa2400326
摘要

BACKGROUND: We conducted a randomized controlled trial to compare intermediate doses (IDAC) with high doses of cytarabine (HDAC) as postinduction therapy in patients 18 to 60 years of age with newly diagnosed acute myeloid leukemia (AML). The main objectives were to evaluate noninferiority in overall survival (OS) after IDAC and safety. METHODS: /12 hours). Patients with intermediate- and adverse-risk AML were eligible for allogeneic hematopoietic stem cell transplantation (HSCT) in first remission. The primary end point was OS in a predefined per-protocol analysis population. The primary analyses were performed in 1132 randomly assigned patients, with a noninferiority outcome adjusted on the European Leukemia Net (ELN) 2022 risk group, the use of induction anthracycline, the response to induction, and HSCT as a function of time following treatment. RESULTS: At 5 years, OS was estimated at 59.3% (95% confidence interval [CI], 55.0 to 63.3) in the IDAC group versus 57.5% (95% CI, 53.3 to 61.5) in the HDAC group (adjusted hazard ratio, 0.96; 95% CI, 0.80 to 1.15; noninferiority test, P=0.0042). A preplanned analysis was unable to detect any interaction between IDAC or HDAC treatment effect and patient subgroups, including those defined by the ELN 2022 risk group or response to induction prior to random assignment. In addition, the severity of chemotherapy-induced myelosuppression and the incidence of related adverse events were lower after IDAC. CONCLUSIONS: Our trial shows noninferior outcomes in patients 18 to 60 years of age with newly diagnosed AML treated with low- versus high-dose cytarabine; this occurred with similar or lower toxicities. (Funded by the Regional Clinical Research Office, Angers and others; EudraCT number, 2014-000699-24; ClinicalTrials.gov number, NCT02416388.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Freeasy完成签到 ,获得积分10
1秒前
1秒前
无人靠岸发布了新的文献求助10
4秒前
比奥利奥还奥的美少女完成签到 ,获得积分10
4秒前
WhiteCaramel完成签到 ,获得积分10
5秒前
酷波er的应助被潘11采纳,获得10
5秒前
然嘻嘻完成签到 ,获得积分10
5秒前
能干冬瓜完成签到,获得积分10
6秒前
7秒前
8秒前
obsession完成签到 ,获得积分10
8秒前
xrwwww发布了新的文献求助10
12秒前
科研通AI6.2的应助被猫猫猫采纳,获得10
14秒前
Jacky完成签到,获得积分10
14秒前
as_eichi发布了新的文献求助10
15秒前
15秒前
16秒前
zyy发布了新的文献求助10
17秒前
Lisa完成签到,获得积分10
17秒前
18秒前
整点可乐完成签到,获得积分10
18秒前
华无剑的应助被sunny采纳,获得10
20秒前
TFoCR7发布了新的文献求助10
20秒前
22秒前
森林完成签到 ,获得积分10
22秒前
BlueStrike完成签到 ,获得积分10
22秒前
研友_VZG7GZ的应助被晴明墨之介采纳,获得10
23秒前
跳跃的凡阳完成签到,获得积分10
23秒前
23秒前
xrwwww完成签到,获得积分10
23秒前
26秒前
ding的应助被zyy采纳,获得10
27秒前
善良的含芙完成签到,获得积分10
28秒前
29秒前
科研通AI6.2的应助被suuuye采纳,获得10
29秒前
法医秦明完成签到 ,获得积分10
31秒前
33秒前
sanqian完成签到 ,获得积分10
35秒前
星星完成签到 ,获得积分10
36秒前
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760